These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 3135160)

  • 1. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy.
    Levy J
    Chest; 1988 Aug; 94(2 Suppl):150S-156S. PubMed ID: 3135160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiresistant pulmonary infection in cystic fibrosis--prevention is better than cure.
    Smyth A
    Lancet; 2005 Aug 6-12; 366(9484):433-5. PubMed ID: 16084235
    [No Abstract]   [Full Text] [Related]  

  • 6. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
    Ratjen F
    Int J Antimicrob Agents; 2001 Feb; 17(2):93-6. PubMed ID: 11165111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
    BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G; Campana S; Festini F; Mascherini M; Döring G
    Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
    Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
    Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
    Coman G; Petraru E; Dahorea C; Anton DT
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial therapy against Staphylococcus aureus, Pseudomonas aeruginosa, and Pseudomonas cepacia.
    Geddes DM
    Chest; 1988 Aug; 94(2 Suppl):140S-145S. PubMed ID: 3293940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
    Valletta EA; Rigo A; Bonazzi L; Zanolla L; Mastella G
    Acta Univ Carol Med (Praha); 1990; 36(1-4):44-5. PubMed ID: 2130717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
    Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
    Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational parameters for antibiotic therapy in patients with cystic fibrosis.
    Govan JR; Doherty C; Glass S
    Infection; 1987; 15(4):300-7. PubMed ID: 3117704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.